Anzeige
Mehr »
Login
Mittwoch, 28.07.2021 Börsentäglich über 12.000 News von 669 internationalen Medien
Countdown: Die derzeit größte Kurswette mit Ansage!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PKSD ISIN: NO0010851603 Ticker-Symbol: 7UM 
Frankfurt
28.07.21
09:16 Uhr
7,060 Euro
-0,210
-2,89 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ULTIMOVACS ASA Chart 1 Jahr
5-Tage-Chart
ULTIMOVACS ASA 5-Tage-Chart
RealtimeGeldBriefZeit
7,1207,41020:33

Aktuelle News zur ULTIMOVACS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.07.Ultimovacs ASA: Ultimovacs' Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines289Oslo, 5 July 2021: Ultimovacs ASAexamines the broad relevance of telomerase as an attractive cancer target and examines opportunities for optimizing anti-telomerase vaccine performance both by selecting...
► Artikel lesen
08.06.Ultimovacs' clinical data presented at ASCO3
ULTIMOVACS Aktie jetzt für 0€ handeln
04.06.Ultimovacs ASA: Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program258UV1/pembrolizumab results in 30% complete responses plus 30% partial responsesGood safety and tolerability profile supports expanded Phase II combination programData highlighted at ASCO in poster presentation ...
► Artikel lesen
01.06.Ultimovacs ASA: Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma1
28.05.Ultimovacs ASA: Mandatory notification of trade by primary insider2
21.05.Ultimovacs - ORR impressive in Phase I UV1 plus Keytruda255Yesterday, Ultimovacs reported the first results from a Phase I trial of UV1 in advanced melanoma in combination with Keytruda. After the minimum 18-month follow-up period (median of 21 months), complete...
► Artikel lesen
20.05.Ultimovacs ASA: Mandatory notification of trade by primary insider1
20.05.New data gives weight to Ultimovacs's cancer vaccine-
19.05.Ultimovacs ASA: Ultimovacs' UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data2
18.05.Shareholder Notification: Ultimovacs ASA-
11.05.Ultimovacs ASA: Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology287Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication in Frontiers in Immunology of its positive long-term Overall...
► Artikel lesen
11.05.Ultimovacs ASA reports Q1 results1
11.05.Ultimovacs ASA: First Quarter 2021 Result Presentation202Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its first quarter 2021 results today. A presentation by the Company's...
► Artikel lesen
10.05.Ultimovacs ASA: Ultimovacs to Discuss ASCO UV1 Phase I Data in Webcast and Investor Meetings269Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that its management team will discuss data from the abstract of a poster...
► Artikel lesen
28.04.Ultimovacs ASA: Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting1
28.04.Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting236Ultimovacs ASA ("Ultimovacs", ticker ULTI) today announced that an abstract on the Company's Phase I trial evaluating its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor...
► Artikel lesen
16.04.Ultimovacs ASA - Share Option Program2
15.04.Ultimovacs ASA - Annual General Meeting held on 15 April 2021-
13.04.Ultimovacs presents INITIUM study design at AACR-
12.04.Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting-
Seite:  Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1